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While modernization has dramatically increased lifespan, it has also witnessed the increasing prev-
alence of diseases such as obesity, hypertension, and type 2 diabetes. Such chronic, acquired dis-
eases result when normal physiologic control goes awry and may thus be viewed as failures of
homeostasis. However, while nearly every process in human physiology relies on homeostatic
mechanisms for stability, only some have demonstrated vulnerability to dysregulation. Additionally,
chronic inflammation is a common accomplice of the diseases of homeostasis, yet the basis for this
connection is not fully understood. Here we review the design of homeostatic systems and discuss
universal features of control circuits that operate at the cellular, tissue, and organismal levels. We
suggest a framework for classification of homeostatic signals that is based on different classes of
homeostatic variables they report on. Finally, we discuss how adaptability of homeostatic systems
with adjustable set points creates vulnerability to dysregulation and disease. This framework high-
lights the fundamental parallels between homeostatic and inflammatory control mechanisms and
provides a new perspective on the physiological origin of inflammation.Introduction
Changes in human ecology—including diet, physical activity,
population density, and microbial exposure—have dramatically
shifted the spectrum of human diseases over the past century.
Genes selected to protect from starvation, infections, injury,
and predation may now, in the absence of some of these chal-
lenges, contribute to the increasing incidence of ‘‘modern human
diseases,’’ including obesity, type 2 diabetes, atherosclerosis,
autoimmunity, allergy, and certain psychiatric disorders. Plau-
sible evolutionary explanations for the high prevalence of these
diseases in industrialized countries include antagonistic pleiot-
ropy (Williams, 1957) and the mismatch between modern envi-
ronment and human evolutionary history (Gluckman et al.,
2009; Stearns and Koella, 2008).
These modern human diseases seem to have two features in
common: they involve disruption of homeostasis, and they are
nearly universally associated with chronic inflammation. Despite
this well-documented connection between inflammation and
diseases of homeostasis, the underlying evolutionary andmech-
anistic bases remain obscure. In most complex diseases, in
contrast to rare Mendelian diseases, the pathological state has
a normal, physiological counterpart. The etiology of modern hu-
man diseases may therefore point to the physiological rationale
connecting inflammation and homeostasis.
Most physiological processes can only operate under a
narrow range of conditions, which are maintained by special-
ized homeostatic mechanisms in the face of variations in
the environment, and adjusted in response to changes in816 Cell 160, February 26, 2015 ª2015 Elsevier Inc.functional demands and biological priorities. Interestingly,
only some of these processes are vulnerable to dysregula-
tion and disease. For example, lipid and glucose metabolism
can be derailed, leading to dyslipidemia, diabetes, and
obesity, while amino acid metabolism seems resistant to ho-
meostatic dysregulation. Here we present a view that may
help explain the differential susceptibility of physiological
processes to diseases of homeostasis. We explore the funda-
mental connections between homeostasis and inflammation
and discuss an evolutionary perspective on homeostatic
diseases.
Homeostatic Variables and Control Circuits
In the 19th century, Claude Bernard articulated the need to main-
tain a stable internal environment—milieu interieur—that would
allow biological processes to proceed despite variations in the
external environment (Bernard, 1878). Bernard’s concept was
further explored, developed, and popularized byWalter Cannon,
who coined the term ‘‘homeostasis’’ in describing how key phys-
iological variables are maintained within a predefined range by
feedback mechanisms (Cannon, 1929). His contemporary, Curt
Richter, expanded the notion of homeostasis to include behav-
ioral responses as an important mechanism by which homeosta-
sis could be regulated in addition to the internal controls systems
described by Bernard and Cannon (Moran and Schulkin, 2000;
Richter, 1943). Nearly two decades after Cannon, James Hardy
proposed a model in which homeostatic mechanisms maintain
physiological variables within an acceptable range by comparing
Table 1. Glossary
Term Definition Examples
Stock A system’s variable that represents quantity Blood glucose concentration




Regulated variable A physiologic variable that is maintained at a stable level (near set
point) by homeostatic circuit(s). Regulated variables are stocks
Blood glucose concentration
Controlled variable A physiologic variable that is manipulated in order to maintain the




Set point An optimal value of the regulated variable; divergence from set
point value activates homeostatic control mechanisms
Normoglycemia (5 mM)
Error value jX-X’j The difference between the set point and the actual value of the
regulated variable
Difference between actual blood glucose
concentration and normoglycemia
Controller A component of the homeostatic circuit that monitors the value of
regulated variable
Pancreatic a and b cells
Plant An effector component of the homeostatic circuit that is activated
by the Controller to change the value of regulated variable
Skeletal muscle, white adipose tissue, brown
adipose tissue, liver
Controller gain A characteristic of Controllers that determines the amount of
signal produced in response to given error value jX-X’j
Amount of insulin produced by b-cells in
response to a given blood glucose level
Gain tuning of Controller A method to optimize Controller performance Changing the amount of insulin produced in
response to a given blood glucose levelthe actual value of the variable to a desired value or ‘‘set point’’
(Hardy, 1953–1954).
Homeostasis is a unifying theme of modern physiology and
much has been elucidated about molecular mechanisms of ho-
meostatic control. However, the term, being intuitively simple,
is often used loosely. For the purpose of this discussion, it is
important to introduce and review some key definitions and con-
cepts initially developed in control theory and systems dynamics
theory, but applicable to homeostatic control in biological sys-
tems (see Table 1 for glossary).
First, it is important to distinguish two types of variables that
exist in homeostatic systems. The physiological variables that
are maintained at a stable level, such as blood glucose or core
body temperature, are called regulated variables. In contrast,
controlled variables are activities, or rates, of the processes
that contribute to the stability of regulated variables (Cabanac,
2006). For example, blood calcium concentration is a regulated
variable, whereas the rate of urinary calcium excretion is a
controlled variable that is manipulated in order to regulate blood
calcium concentration. Multiple controlled variables typically
contribute to the stability of a given regulated variable. Thus, in
addition to calcium excretion in the kidney, the rates of intestinal
calcium absorption and bone resorption are also controlled vari-
ables that contribute to the maintenance of stable blood calcium
concentration. In the case of blood glucose concentration
(a regulated variable), the controlled variables include the rates
of intestinal and renal glucose transport, glycogenolysis, gluco-
neogenesis, glycolysis, glycogenesis, and glucose transport
from the blood into tissues. Thus, regulated variables refer to
quantities, whereas controlled variables refer to processes,
where process activity or rate is a variable. Put in systems dy-
namics terms, regulated variables are the stocks of the system,
while controlled variables are the flows of the system: they eitherincrease (in-flows) or decrease (out-flows) the value of the regu-
lated variable (Figure 1). Notably, while all regulated variables are
stocks, not all stocks are regulated variables. For example blood
glucose is a regulated variable, whereas blood alcohol is not.
Likewise, all controlled variables are flows, but not all flows are
controlled variables. Thus heat loss through sweating is a
controlled variable, while heat loss through conduction is not.
Because these terminologies capture different aspects of sys-
tem behavior we will use both during this discussion, to empha-
size the relevant features of homeostasis.
In order to be maintained within the desired range, the values
of regulated variables must be continuously monitored and
adjusted. Accordingly, all homeostatic systems have two essen-
tial components: Controllers and Plants. The Controllers monitor
the value of the regulated variable (X), compare it to the reference
value (or in Hardy’s terms, set point) (X’), and generate a
signal that is proportional to the absolute value of the difference
jX - X’j (the coefficient of proportionality is a characteristic known
as the Controller’s gain) (A˚stro¨m and Murray, 2008). This signal
then acts on the Plant—the effector that creates flows into or
out of the system—in order to bring the regulated variable closer
to the reference value (Figure 2A). In a classic engineering
example of a control system, the thermostat (Controller) com-
pares the actual room temperature (regulated variable) to the
desired room temperature (reference value, or set point). If actual
room temperature is lower than the set point, a signal is
generated and sent to the furnace (the Plant) to increase heat
production (the flow) and raise room temperature toward the
set point value. In physiology, the Controllers are typically endo-
crine cells and sensory neurons of the autonomic nervous sys-
tem, lower brainstem (medulla), and hypothalamus (Hammel,
1968). Theymonitor deviations in regulated physiologic variables
from their set points and generate signals (hormones andCell 160, February 26, 2015 ª2015 Elsevier Inc. 817
Figure 1. Stock and Flow Model of Homeostasis
(A) Stock and flow model highlights two types of variables in homeostasis:
Stock is quantity of a regulated variable - a parameter that is maintained by
homeostasis. Flows are the processes that change the value of the stock.
Some, but not all flows are controlled variables and targets for homeostatic
control signals (graphically represented here as dials). Clouds represent
‘‘sources’’ and ‘‘sinks’’ for regulated variable that are extrinsic to the homeo-
static system.
(B) A physiologic example of stock and flow model: dietary glucose uptake,
hepatic glucose production, or glucose uptake into adipose and muscle are
flows that maintain the stock of blood glucose.
Figure 2. Homeostatic Control Circuit
(A) Basic homeostatic control circuits have two essential components: Con-
trollers and Plants. Controllers monitor the value of regulated variable (X) and
compare it to the reference value (X’). In response to deviation of X from X’,
Controllers generate a signal (S) that acts on Plants. Plants are the effectors of
the homeostatic systems that change the value of the regulated variable.
(B) A physiologic example of control circuit: pancreatic beta cells act as
Controller, sensing elevated blood glucose and producing insulin (signal S) to
increase glucose uptake into skeletal muscle (Plant). In the simplest model, the
output of the Controller (signal S) is proportional to the deviation of regulated
variable from the reference value, jX-X’j. The proportionality constant is
referred to as the gain.
(C) Combining stock and flowmodelingwith the basic control circuit provides a
more complete model of homeostasis. The Controller monitors the value of the
Stock and produces signals that act on Plants. Such signals cause Plants to
modulate the flows that contribute to the Stock. In this example, glucose
sensing by the pancreas (Controller), induces glucagon or insulin secretion
(Signals S’ and S’’), which act on liver and muscle (Plants), to control glucose
production and uptake, respectively (flows) and stabilize blood glucose
(Stock).neurotransmitters) that increase or decrease the flows created
by various Plants (tissues and organs that can adjust these
values) (Figure 2B). For example, pancreatic b-cells (Controller)
produce insulin in response to an increase in blood glucose
(regulated variable). Insulin acts on skeletal muscle, adipose tis-
sue, and liver (the Plants) to increase glucose uptake and utiliza-
tion (out-flows) in muscle and fat and to inhibit gluconeogenesis
(in-flow) in the liver, thereby reducing plasma glucose level
(Figure 2C).
Controllers and Plants are defined with respect to specific
regulated variables. For example, pancreatic a- and b-cells are
Controllers for blood glucose, but not for body temperature,
whereas adipose tissue and liver are Plants for blood glucose,
but not for blood calcium (where the relevant Plants are the kid-
ney, intestine, and bone). Additionally, most tissues and organs
perform many functions and can therefore act as Plants for mul-
tiple regulated variables, depending on the requirements of the
organism: because skeletal muscle can both consume glucose
and generate heat during shivering thermogenesis, it can act
as a Plant for both blood glucose and body temperature. Thus,
Controllers are characterized by the regulated variables they
monitor, while Plants are characterized by the controlled vari-
ables (activities of the flows) associated with them.818 Cell 160, February 26, 2015 ª2015 Elsevier Inc.Fifty years after its inception, there is still disagreement over
Hardy’s concept of set point, which in his model was analogous
to the reference value of engeneered systems. Some argue that
regulated variables can reach steady state or ‘‘settling point’’
without an external reference point (Wirtshafter and Davis,
1977). In stock and flow terms, the stock would not be regulated
by comparison to a set point, but simply reach a passive ‘‘settling
point’’ when in-flows and out-flows balance. In other words, one
can think of set point as being either a predefined, or an emer-
gent characteristic of a system. A full discussion of the strengths
and limitations of these two models is beyond the scope of this
article. However, the two models may not necessarily be mutu-
ally exclusive (Speakman et al., 2011). Regardless of whether a
reference point is real or imaginary, the term set point, if nothing
else, is a convenient shortcut by which to refer to the defended
Figure 3. Homeostatic Units
(A) System stock, Plant stock and Storage stock each represent homeostatic
units that are connected by flows. Each of the stocks is monitored by a
specialized Controller, which regulates the flows into and out of the stock.
Homeostatic system is thus hierarchically organized into ‘‘nested’’ homeo-
static units.
(B) Physiologic example of nested homeostatic units: System stock (blood
glucose) is monitored by System Controller (pancreatic b-cells), Plant stock
(glucose in skeletal muscle) is monitored by Plant specific Controller (e.g.,
AMPK) and Storage stock (muscle glycogen) is presumably monitored by a
glycogen sensor, which is currently unknown. Each of the Controllers regu-
lates the flows into and out of the corresponding stock.level of a regulated variable and will be used herein for simplicity.
For the sake of this discussion, it should not be thought of
as equivalent to the external reference value in engeneered
systems.
Homeostatic Units
Homeostasis has been studied primarily with regard to system-
ically regulated variables such as plasma glucose level and core
body temperature. However, many of the same variables are
also homeostatically maintained at the level of individual cells
within tissues. Such variables are referred to as System stocks
when they are maintained at the systemic level and Plant stocks
when they are maintained at the level of individual Plants.
Thus, while blood glucose (System stock) is maintained by insu-
lin, glucagon, and catecholamines, glucose level in skeletal mus-
cle (Plant stock) is simultaneously monitored by intracellular
sensors and homeostatically maintained through regulated
expression of glucose transporters and activity of metabolic
pathways of glucose utilization (Herman and Kahn, 2006; Jensen
et al., 2008). On the organismal level, pancreatic b-cells function
as Controllers and skeletal muscle as Plants. Within individual
myocytes, AMPK functions as a Controller (monitoring intracel-
lular glucose level) and GLUT4 (a glucose transporter) functions
as a Plant. The signal connecting Controllers to Plants in this
case is the signaling pathway connecting AMPK to GLUT4
expression. Note that System stock and Plant stock are con-
nected by a flow (e.g., glucose transport from blood into skeletalmuscle by GLUT4) (Figure 3). GLUT4 expression and glucose
flow can be controlled by both the system level Controller (in
this case, by insulin) and by the tissue level Controller (in this
case, by AMPK). In exercising muscle, for example, glucose
and ATP depletion leads to AMPK activation, prompting insu-
lin-independent glucose uptake (a tissue-level control) even
when insulin-stimulated uptake might be suppressed (a sys-
tem-level control) (Herman and Kahn, 2006; Russell et al.,
1999). Conversely, when skeletal muscle energy stores are
high, insulin-dependent glucose uptake is inhibited, as illustrated
by insulin resistance that can be caused by fatty acid accumula-
tion in the muscle (Samuel and Shulman, 2012) or by activity of
the hexosamine biosynthetic pathway (Ruan et al., 2013).
Some Plant stocks have a special property: glycogen in the
liver and muscle, triglycerides in the adipose tissue, and calcium
phosphate in the bone are examples of Storage stocks. They
buffer regulated variables (blood glucose, fatty acids, and cal-
cium) from the variations in dietary intake or expenditure. The
System stocks (e.g., blood glucose), Plant stocks (muscle
glucose) and Storage stocks (muscle glycogen) are connected
by in- and out-flows (glucose transport, glycogenolysis, and
glycogenesis), which are adjusted by hormones and neurotrans-
mitters to maintain the System stock within a desired range
(Figure 3). The relationship between regulated stocks and stor-
age stocks is analogous to the relationship between pocket
money and money in a bank account: they are connected by
flows (deposits and withdrawals) and while the former is usually
maintained within a relatively narrow range, the latter is not. Stor-
age stocks exist for some regulated variables (glucose, fatty
acids, vitamin A, calcium), but not for others (oxygen, sodium,
potassium). Accordingly, the latter variables are more vulnerable
to fluctuations in environmental availability.
As noted earlier, Plants are defined by the regulated variables
they maintain. The notion of the Plant is only relevant with
respect to a specific homeostatic circuit. When skeletal muscle
is referred to as a Plant in glucose homeostasis, it is specifically
its activities in glucose handling that are relevant. In that sense
the terms ‘‘Plant’’ and ‘‘Tissue’’ are not equivalent. All tissues
have their own homeostatic circuits that may or may not be
related to their function as Plants or Controllers. Like any homeo-
static systems, tissues have their own regulated and controlled
variables. Oxygen and nutrient concentration, interstitial fluid
volume, pH, osmolarity, cell number, and cellular composition
are all examples of regulated variables of tissue homeostasis
(Chovatiya and Medzhitov, 2014). Cell proliferation, apoptosis
and migration, lymphatic drainage, and vascular permeability
are examples of controlled variables. Typical Controllers include
tissue resident macrophages, mast cells, and somatosensory
neurons, all of which monitor various regulated variables of tis-
sue homeostasis. Finally, many cells within tissues (including
vascular and lymphatic endothelium, stromal, and parenchymal
cells) can act as Plants, depending on the controlled variable
(Chovatiya and Medzhitov, 2014).
As noted earlier, some regulated variables, for example,
glucose, are homeostatically maintained as System stock (blood
glucose), Plant stock (muscle glucose), and Storage stock (mus-
cle glycogen). All three stocks are connected by flows. However,
not all regulated variables are connected in this manner: forCell 160, February 26, 2015 ª2015 Elsevier Inc. 819
example, protein concentration in a cell and in plasma are both
regulated variables, but they are not connected by flows;
collagen stiffness/elasticity is a regulated variable of tissue ho-
meostasis, but it does not even have a counterpart at cellular
or organismal levels. When a regulated variable is maintained
by homeostatic circuits at multiple levels that are connected by
flows, the result is interdependent, ‘‘nested’’ homeostatic units
(Figure 3). This hierarchical organization of homeostasis pro-
vides buffering and flexibility in addressing systemic and tis-
sue-specific physiologic needs and priorities.
Controllers as Sensors of Regulated Variables
Controllers play a key role in homeostasis by monitoring the
values of the regulated variables. There are two methods used
by Controllers to perform this function. SomeControllersmonitor
the values of regulated variables through a flow that samples the
System stock. As an example, b-cells monitor blood glucose
level by transporting glucose through GLUT2 transporter and
converting it by glucokinase into glucose-6-phosphate (G6P) to
initiate glycolysis (Olson and Pessin, 1996). ATP generated by
glycolysis then inhibits the ATP-sensitive potassium channel re-
sulting in plasma membrane depolarization, calcium influx, and
insulin secretion (Newgard et al., 2002; Newgard and McGarry,
1995). The flow of glucose into b-cells has special features that
enable glucose sensing: First, GLUT2 has a very high Km for
glucose (15-20 mM) and only transports glucose when its level
in the blood is high (Burant and Bell, 1992). Similarly, glucokinase
has a low affinity for glucose compared to other hexokinases
(Matschinsky, 1996). These properties make the b-cell sensitive
to high plasma glucose level. Second, the flows into Controllers
are not subject to inhibition by negative feedback, unlike the
flows into Plants. Thus, glucokinase, unlike hexokinases, is not
inhibited by G6P (Matschinsky, 1996); otherwise the amount of
ATP generated by glycolysis would not be proportional to the
amount of glucose transported into the b-cells.
An alternative means by which to monitor the system stock is
through dedicated receptors. For example, sensory neurons
typically use various gated channels and other sensors to
monitor temperature (e.g., TRMP8 and TRPV1), pH (ASICS),
oxygen (pO2 sensor in glomus cells of carotid body), and stretch
sensors in baroreceptors (Krishtal, 2003; Montell, 2005; Prabha-
kar, 2000). Many metabolites, for example, fatty acids and ke-
tones, can be monitored both directly by GPCRs (Briscoe
et al., 2003; Oh et al., 2010) and through their flow into Control-
lers where they are metabolized.
Physiological Priorities
As Cannon aptly noted when selecting the prefix homeo, or
similar, rather than homo, same (Cannon, 1929), homeostatic
variables are not maintained at a constant level, but rather within
a certain range of values. Some physiological variables (e.g.,
plasma glucose) are tolerated over a relatively wide dynamic
range, while others must remain within a narrow range (e.g.,
plasma calcium). Moreover, the same regulated variable can
have a different acceptable dynamic range in different tissues:
for example, the brain has low tolerance to deviations in many
physiologic variables (including oxygen, glucose, and tempera-
ture) while white adipose tissue is typically less demanding.820 Cell 160, February 26, 2015 ª2015 Elsevier Inc.Thus, the most sensitive tissues both define the limits of homeo-
static range for the corresponding regulated variables and tend
to be better protected from the fluctuations in these variables.
For example, the brain is relatively insulated from the normal vari-
ation of blood glucose levels (ranging between 4 mM and 7 mM)
due to the neuronal expression of the high-affinity glucose trans-
porter GLUT3, which has a low KM for glucose (1 mM) (Burant
and Bell, 1992).
Homeostatic prioritization is also reflected in the contribution
of the different Plants to the maintenance of the regulated vari-
able. As eluded to earlier, a given regulated variable can be
affected by multiple Plants. For example, blood glucose level
can be affected by muscle, liver, adipose, kidney, and intestine
through uptake, metabolism, and excretion. The relative contri-
butions of different Plants to blood glucose level need to be co-
ordinated to minimize fluctuation of the stock. Thus, increased
glucose consumption by exercising skeletal muscle can be
compensated for by decreased consumption by the adipose tis-
sue and/or by increased gluconeogenesis by the liver. While all
three Plants can affect the value of the regulated variable (in
this case glucose), their relative contributions can change de-
pending on their functional states and physiological priorities of
the organism. The corollary to this feature is that increased
flow burden is dynamically allocated between different Plants,
which in turn necessitates communication between Plants to co-
ordinate their contributions to systemic homeostasis, as we
discuss next.
Homeostatic Control Signals
The classical view of homeostasis is that it is maintained by sig-
nals from the endocrine and autonomic nervous systems.
Recent discoveries have extended this paradigm by demon-
strating that signals produced by tissues and organs not histor-
ically thought of as endocrine organs—including adipose tissue,
the intestine, the liver, the muscle, and the kidneys—also play
critical roles in homeostatic control. Examples of these signals
include the adipokines leptin (Friedman and Halaas, 1998), adi-
ponectin (Yamauchi et al., 2001), and RBP4 (Yang et al., 2005);
the hepatokine FGF21 (Fisher et al., 2011); the myokines IL-6
(Pedersen and Febbraio, 2012) and meteorin-like (Rao et al.,
2014); and the gut hormones FGF15/19 (Potthoff et al., 2011),
CCK (Gibbs et al., 1973), and GLP-1 (Holst, 2007). While the
mechanisms of action of many of these signals are still being
elucidated, one could argue that not all signals are equivalent
in the type of information they communicate within a homeo-
static circuit.
As discussed above, there are two types of variables in ho-
meostasis: stocks and flows. The stocks can be further divided
into System stocks (e.g., plasma glucose), Plant stocks (e.g.,
muscle glucose), and Storage stocks (e.g., muscle glycogen).
We propose that each type of stock and flow is monitored and
translated into a distinct class of homeostatic signals that reports
on their value (Figure 4), giving rise to four classes of homeostatic
signals:
(1) Signals of the first class are produced by System Control-
lers and report on the value of the System stocks (Signal
Sa in Figure 4). These are classical endocrine hormones
Figure 4. Four Classes of Signals Control
Systemic Homeostasis
(A) Four classes of homeostatic signals report on
values of four different types of variables: System
stock (regulated variable), Plant stock, Storage
stock and Flows. Each stock and the flows are
monitored by dedicated Controllers and sensors.
All four categories of homeostatic signals modu-
late gain tuning of Controllers and flow tuning in
Plants. Signals that report on stocks operate in
feed-back loops. Signals that report on flows op-
erate in feed-forward loops.
(B) Signals reporting on the System stock (Sa) are
classical endocrine hormones and efferents of the
autonomic nervous system (e.g., insulin and
glucagon). Signals reporting on Plant stocks (Sb)
primarily operate in a cell or tissue autonomous
manner (e.g., AMPK controlling GLUT4 expres-
sion), but may include signals acting systemically
(e.g., AMPK controlling IL-6 expression in exer-
cising muscle). Signals reporting on Storage
stocks (Sc) indicate available resources (e.g., lep-
tin reporting on fat stores). Finally, signals report-
ing on Flows (Sd) indicate anticipated changes in
the System stock (e.g., GLP-1 reporting on
incoming glucose). The examples are chosen to
illustrate the point.and efferents of the autonomic nervous system that oper-
ate in negative feedback loops. Examples include insulin
and glucagon reporting on plasma glucose level, or para-
thyroid hormone reporting on plasma calcium level.
(2) Signals of the second class report the value of the Plant
stocks (Signal Sb in Figure 4). Plant stocks are monitored
by cell or tissue specific Controllers, such as AMPK,
mTOR, HIF-1a, stretch receptors and many others. These
sensors generate negative feedback signals that control
the flows into Plant stocks in a cell or tissue autonomous
manner (such as the example of insulin-independent
glucose uptake in exercising muscle, described above).
Additionally, Plants produce signals that control the flows
in a systemic manner. Signals of this category include
various myokines, such as IL-6 and meteorin-like (Peder-
sen and Febbraio, 2012; Rao et al., 2014), which appear to
report on fuel depletion in muscle.
(3) Signals of the third class report the value of Storage
stocks (Signal Sc in Figure 4). For example, leptin reports
on the available fat storage in adipose tissue, and there-
fore controls food intake (caloric inflow) and energy
expenditure (caloric outflow) (Friedman and Halaas,
1998). Hepcidin, similarly, reports on the storage stock
of iron in the reticuloendothelial system in order to inhibitCell 160, Febdietary iron uptake and prevent
iron overload (Nemeth et al.,
2004). Signals reporting on avail-
able glycogen stores are not
known but are likely to exist. Sig-
nals of this class also participate
in negative feedback circuits.
(4) Signals of the fourth class report
the values of flows (Signal Sd in
Figure 4). For example, the guthormone, GLP-1, reports on dietary glucose inflow, and
therefore anticipates rising systemic glucose stock
(which is itself reported by insulin) (Holst, 2007). CCK
and NAPEs (N-Acylphosphatidylethanolamines) similarly
report on dietary fat inflow and reduce appetite to sup-
press further inflow (Gibbs et al., 1973; Gillum et al.,
2008). FGF21 is produced by hepatocytes during
fasting (Badman et al., 2007; Inagaki et al., 2007) and
potentially reports on flow of fatty acids from the adipo-
cytes during lipolysis. FGF21 expression in the liver is
induced by fatty acids through PPARa (Potthoff et al.,
2012). One might speculate that while PPARg sensing of
fatty acids in adipose tissue is an indicator of the inflow
into the fat storage stock (taking place during feeding-
associated lipogenesis), PPARa sensing of fatty acids
in the liver is an indicator of the outflow from the
storage stock (taking place during fasting-induced lipol-
ysis). One important feature of signals that report on
flows is that they typically operate in a feed-forward
fashion. Because a change in a flow is predictive of the
subsequent change in the stock, the signal reporting
on an increased inflow, for example, would be expected
to increase the outflow and inhibit other inflows of the
same stock. This is in contrast to signals that report onruary 26, 2015 ª2015 Elsevier Inc. 821
the System, Plant, and Storage stocks, which all operate
in a feedback fashion to maintain the stock within an
acceptable range.
Monitoring the flows enables the system to minimize time de-
lays that are unavoidable in negative feedback systems. React-
ing to changing flows elicits an anticipatory response that
makes the homeostatic system more robust to environmental
fluctuations and helps to prevent dramatic changes in the
stock. For example, intestinal glucose in-flow reporting by
GLP-1 helps to prevent dramatic postprandial glucose spikes
that would be unavoidable if only stock (blood glucose) report-
ing by insulin were available. Not every flow in the system needs
to be monitored and reported as a signal. Presumably, only the
flows that have a major impact on the system’s stock are moni-
tored, particularly the flows that operate at the interface with the
environment (for example, in the intestine, liver, kidney, lungs,
and skin).
The four categories of signals outlined above are defined by
the homeostatic variables they report on. The effects of homeo-
static signals fall into three categories: First, homeostatic signals
directly regulate the flows of the system: for example, insulin
suppresses hepatic gluconeogenesis. Second, homeostatic
signals can change the sensitivity of the flows to another homeo-
static signal: for example, placental hormones and glucocorti-
coids reduce the sensitivity of target tissues to insulin. Third,
homeostatic signals can change the gains of the Controllers.
For example, GLP-1 increases and leptin decreases the gain of
the pancreatic b-cells – they change the amount of insulin pro-
duced in response to a given level of blood glucose. Thus, in
addition to adjusting the flows of Plants, homeostatic signals
can change the gains of Controllers.
In summary, a complex array of signals reporting on available
stocks and flows allows Controllers to coordinate multiple Plants
toward regulation of a homeostatic variable, while simulta-
neously balancing the needs and capabilities of individual Plants.
Thus, application of the ‘‘stock and flow’’ model provides a
framework for functional classification of homeostatic signals
and extends the traditional model of homeostasis, which is
focused exclusively on Controller-to-Plant signals.Adjustable Set Points and Homeostatic Adaptation
Homeostatic circuits can be broadly divided into two classes—
those that have a single fixed set point and those with multiple
or adjustable set points. The fixed set point circuits are charac-
teristic of regulated variables that have a narrow dynamic range,
such as arterial [pO2] or blood calcium concentration. Homeo-
static systems with fixed set points are regulated solely by
changing the flows, such as calcium resorption, excretion, stor-
age, and utilization. The adaptability of systems with a single set
point is limited by the homeostatic range of the regulated vari-
able; when the regulated variable deviates beyond the accept-
able range (for example in extreme environments when the
buffering capacity of the system is overwhelmed), the system
can undergo catastrophic pathological changes. The failure of
one homeostatic circuit may lead to a disruption of other con-
nected circuits, resulting in particularly dangerous scenarios of
cascading failures, as seen, for example, in sepsis.822 Cell 160, February 26, 2015 ª2015 Elsevier Inc.In some cases, the changing environment or physiologic de-
mands cannot be accommodated by homeostatic circuits with
a fixed set point. In these cases, adjustable set points can be em-
ployed to maintain regulated variables within different dynamic
ranges and enable more efficient adaptation to varying de-
mands. This ability to maintain conditions ‘‘at changing rather
than similar levels or values’’ has been referred to as rheostasis
(Mrosovsky, 1990).
There are several examples of homeostasis with variable set
points. Among the most obvious is fever, where the set point
for core body temperature rises and is maintained at a higher
level (as opposed to hyperthermia, where homeostatic mecha-
nisms are engaged to return the temperature to the default set
point). An extreme example of set point change is seen during hi-
bernation: normally, ground squirrels exhibit an average daily
body temperature near 37C. During hibernation, however, their
temperature may fall below 0C and metabolic rate is dramati-
cally suppressed (Barnes, 1989). This extreme physiologic
switch is thought to permit adaptation to conditions of food scar-
city that would be incompatible with life if the squirrels main-
tained their normal metabolic and temperature set points.
Similarly, in human pregnancy, many physiologic parameters
such as blood pressure, blood glucose, total body water, and
adiposity are dramatically altered in order to meet the needs of
the fetus (King, 2000). These set point adjustments can occur
even in a stable environment and reflect the adaptation to chang-
ing physiological priorities. Thus, a variety of environmental fac-
tors and changing physiological priorities, including seasonal
and circadian changes, reproductive status (puberty and preg-
nancy), stress, nutrition, and infection, require homeostatic
adaptations which in some cases appear to involve set point
adjustments.
The change of the set points can occur in two different ways,
depending on whether the set point-adjusting stimulus has to be
continuously present to maintain a new set point value. The
change of the body temperature set point during fever is induced
by prostaglandin PGE2, which acts on thermoregulatory hypo-
thalamic neurons (Romanovsky et al., 2005). As soon as inflam-
mation subsides (or PGE2 production is blocked by COX2
inhibitors), the temperature set point changes back to the original
value of 37C. Thus, in this case, the continuous presence of
PGE2 is required to maintain the altered set point for body tem-
perature. The implication of this is that although all set points are
defended, not all set points are equally stable: 37C is the default
set point for human body temperature, whereas set points
induced by fever are not. As soon as the inducing stimulus sub-
sides or is blocked, the system switches back from the induced
set point to the default set point. This design feature provides a
failsafe to prevent permanent and pathological shifts in the set
point by requiring persistent stimulation. In contrast, the set point
for human body weight appears to be maintained at multiple
alternative stable states. The homeostatic systems that have
alternative stable states without a default set point are particu-
larly vulnerable to dysregulation, as we discuss next.
Set Points and Diseases of Homeostasis
In contrast to circuits with fixed set points, which are generally
robust to perturbations, homeostatic circuits with adjustable
set points are vulnerable to dysregulation precisely because they
are designed to be adjustable. For example, the adjustable set
point for body weight and adiposity allows for adaptation to
times of food abundance or scarcity, as well as to the accumu-
lation of fuel stores to feed a growing fetus. However, in the
setting of the modern environment, adjustable set points may
have contributed to the current obesity epidemic (Speakman
et al., 2011; Woods and Ramsay, 2007). If body adiposity had
a fixed set point value, obesity would be impossible except for
purely genetic reasons. In fact, most tissues other than visceral
fat, have a single set point value for their size control as a function
of body size, which is why they are not subject to homeostatic
dysregulation. Like adiposity, glucose, and lipid homeostasis
are characterized by adjustable set points, while amino acid
and purine/pyrimidine metabolism appear to have a single set
point; accordingly, the former are vulnerable to homeostatic dys-
regulation while the latter are not.
One disease state particularly interesting from this perspective
is insulin resistance. Insulin’s best-known function is to stimulate
glucose uptake by skeletal muscle and adipose tissue, thereby
reducing glycaemia. However, it is now appreciated that insulin
has myriad effects, orchestrating a coordinated anabolic effort
by liver, skeletal muscle, and white adipose tissue to convert
glucose and fatty acids into glycogen and triglycerides, respec-
tively, to export these when necessary for storage in the appro-
priate organ, and to suppress the mobilization of stored fuels
(Schenk et al., 2008; Shulman and Petersen, 2011). In addition,
insulin induces a trophic response in many cell types that pro-
motes protein synthesis, and consequently cellular and tissue
growth (Shulman and Petersen, 2011). Interestingly, not all of
these functions are reduced during the insulin resistant state
(Brown and Goldstein, 2008), nor are all organs equally affected.
Thus, insulin resistance is not equivalent to reducing the quantity
of insulin in the blood, but rather is a method of physiologic set
point adjustment that allows the organism to reallocate re-
sources between different tissues.
Insulin sensitivity can be changed in many altered physiologic
states. During pregnancy, critical illness, infection, and stress,
insulin responsiveness is diminished, presumably to allocate re-
sources toward a growing fetus, tissue repair, or the immune
system, respectively (Odegaard and Chawla, 2013; Power and
Schulkin, 2012; Watve and Yajnik, 2007). Conversely, insulin
sensitivity is heightened during caloric restriction and weight
loss, perhaps to increase anabolic efficiency.
Unfortunately, the adjustability of the insulin sensitivity set point
also makes it vulnerable to disease. Insulin resistance is widely
accepted as the pathological precursor for diabetes, a dangerous
potential complication of obesity. Thus, the verymechanisms that
evolved tomake insulin receptor sensitivity adjustable alsoenable
pathological insulin resistance. The same argument applies to
other homeostatic systems with multiple set points that corre-
spond to alternative stable states—they are vulnerable to dysre-
gulation because they are designed to be adjustable.
As noted above, some homeostatic systems with multiple set
points have a default set point value and any change of set point
has to be actively maintained. Such systems, including control of
body temperature, are generally less vulnerable to dysregulation
because alternative set points are not stable.Inflammation and Homeostatic Circuits
Inflammation is a protective response to extreme challenges to
homeostasis, such as infection, tissue stress, and injury. Inflam-
matory signals—including cytokines, chemokines, biogenic
amines, and eicosanoids, induce myriad changes in diverse bio-
logical processes, ranging from local vascular responses to
alterations of body temperature. Despite this complexity and di-
versity of functions, all the activities of inflammatory signals can
be described in terms of their effects on homeostatic circuits:
First, inflammatory signals can directly stimulate or inhibit the
flows of various homeostatic systems. For example, TNF and
IL-1b activate lipolysis, inhibit gluconeogenesis, and increase
vascular permeability to fluids and solutes, while IL-6 changes
hepatic protein synthesis (Medzhitov, 2008). Second, in addition
to directly affecting the flows, inflammatory signals can change
the sensitivity of the Plants to homeostatic signals. For example,
TNF makes liver, fat, and skeletal muscle less sensitive to insulin
(Hotamisligil et al., 1993; Weisberg et al., 2003). Third, inflamma-
tory signals can change the gain of the Controllers. For example
TNF and IL-1b suppress expression of GLUT2 and glucokinase
in pancreatic b-cells, thus making them less sensitive to the
blood glucose level (Park et al., 1999). Consequently, b-cells pro-
duce less insulin given the same amount of plasma glucose—an
example of gain tuning of the Controller. As discussed above,
homeostatic signals also operate by directly regulating flows,
by changing sensitivity of Plants to other homeostatic signals,
and by gain-tuning of Controllers. Thus homeostatic and inflam-
matory signals employ identical methods to change the same
homeostatic variables (Figure 5).
Importantly, the inflammatory mediators are both antagonistic
to and dominant over homeostatic signals. They are antagonistic
because normal homeostasis is often incompatible with the
goals of the inflammatory response, and the former has to be
temporarily disengaged. Inflammatory signals are dominant
because they have higher physiological priority as they orches-
trate the protective response to life threatening insults of infec-
tion and injury. Thus, homeostatic control of body temperature
(thermogenesis or sweating) is normally induced by changes in
ambient temperature. However, acute inflammation overrides
this control by raising the set point of body temperature, thereby
inducing thermogenesis and fever regardless of ambient tem-
perature. Likewise, acute inflammation-induced anorexia sup-
presses caloric intake regardless of the adiposity, circulating
nutrient concentrations, or body weight.
It is increasingly appreciated that chronic inflammation is an
important component of numerous disease states including
obesity, type 2 diabetes, atherosclerosis, asthma, and neurode-
generative diseases. One potential mechanism by which inflam-
mation may initiate or perpetuate disease is through set point
changes. In obesity, for example, macrophages and other cells
of the immune system infiltrate adipose tissue in response to
the increased burden of lipid accumulation and adipocyte stress
(Hotamisligil and Erbay, 2008; Weisberg et al., 2003). These cells
produce inflammatory cytokines that are capable of shifting ho-
meostatic set points in states of chronic inflammation, just as
they do in acute inflammatory states. The rationale for transiently
adjusting the insulin responsiveness in acute inflammation is
presumed to be in shifting nutrient allocation from tissues thatCell 160, February 26, 2015 ª2015 Elsevier Inc. 823
Figure 5. Inflammatory Signals and Homeostasis
(A) Inflammatory signals (IS) act through the same control points (Plants flows
and Controller gains) as homeostatic signals (HS). To illustrate the parallels
between homeostatic and inflammatory signals, the source of inflammatory
signal is referred to as Inflammatory Controller (e.g., macrophage), by analogy
to Homeostatic Controller (e.g., endocrine pancreas).
(B) Macrophages produce TNF and IL-1which act on the same flows as insulin,
but in opposite direction: TNF and IL-1 induce insulin resistance and suppress
lipid storage in adipose tissue by inhibiting lipoprotein lipase. In addition, these
cytokines induce gain tuning of the pancreatic b-cells to reduce the amount of
insulin produced in response to a given level of blood glucose. This effect is
achieved in part by suppressing glucose flow into b-cells.have lower priority during infection (adipose and skeletal muscle)
toward the higher priority immune defenses (Hotamisligil and
Erbay, 2008). In obesity, chronic inflammation may contribute
to the shift of insulin sensitivity to an alternative set point.
Inflammation is a protective response that is engaged to
defend and restore physiological functions when homeostatic
mechanisms are insufficient. The inflammatory response can
only achieve this goal by overriding or suppressing incompatible
homeostatic controls. However, in its attempts to restore ho-
meostasis, inflammation may enforce and propagate homeo-
static set point changes that are detrimental and can result in824 Cell 160, February 26, 2015 ª2015 Elsevier Inc.chronic pathological states. This happens when a persistent
change in the set point itself creates a problem sufficient to pro-
mote inflammation. For example, hyperglycemia can lead to
glucose toxicity and tissue damage, which in turn can lead to
secondary inflammation. Similarly, the abnormal accumulation
of harmful lipid mediators (lipotoxicity) in adipocytes, liver, and
muscle in obesity leads to cellular stress and tissue dysfunction,
and consequently to inflammation (DeFronzo, 2010; Samuel and
Shulman, 2012; Summers, 2006). Thus, a homeostatic perturba-
tion initially induced by lipotoxicity may be further perpetuated
by inflammation. In such scenarios, a vicious cycle can ensue
that may explain the chronicity of some homeostatic diseases
and their perpetuation by inflammation. Such a model is consis-
tent with data demonstrating that inflammation is dispensable for
the initial induction of insulin resistance, but contributes to main-
taining and even worsening insulin resistance in states of chronic
obesity (Oh et al., 2012).
Successful inflammatory response is followed by the resolu-
tion phase that restores homeostasis. However, because inflam-
mation is induced by loss of homeostasis, but also intentionally
disrupts incompatible homeostatic processes, the system has
the potential to become locked in a state of a chronic inflamma-
tion that fails to resolve. The non-resolving inflammation may, in
turn, account for the persistence of chronic diseases (Nathan
and Ding, 2010; Serhan et al., 2007). It is therefore important to
identify the mechanisms responsible for physiological shifts be-
tween alternative stable states of the homeostatic systems, as
the same mechanisms could be employed therapeutically to
reverse pathological states in chronic diseases of homeostasis.
Perspectives: Evolution, Adaptation, and Disease
The concept of adaptability as vulnerability is pervasive in many
forms of phenotypic variation, be they reversible (body weight) or
irreversible (body height), continuous (reaction norms) or discon-
tinuous (polyphenisms). Traits that are discontinuous are ex-
pressed through one of several alternative developmental
pathways, a phenomenon known as phenotypic plasticity (Dew-
itt et al., 1998; Feinberg, 2007; Stearns and Koella, 2008). Such
plasticity can allow for different phenotypes in the same organ-
ism, and can therefore afford greater adaptability. The choice
of a particular developmental pathway is dictated by anticipation
of certain environments where these pathways and associated
traits would provide greater adaptation. However, if the environ-
ment is not as anticipated and the phenotypic choice is irrevers-
ible, maladapted phenotypes susceptible to disease may result
(Dewitt et al., 1998; Feinberg, 2007; Stearns and Koella, 2008).
Consequently, the mechanisms that afford greater adaptability
can also create vulnerability to diseases (Bateson et al., 2004).
Thus, phenotypic plasticity can be thought of as a develop-
mental equivalent of homeostasis with alternative stable states
dictated by adjustable set points.
The homeostatic capacity of an organism determines its ability
to adapt to varying environments. Homeostatic systems with
fixed set points are inflexible but resistant to dysregulation. If
their buffering capacity is overwhelmed, the consequences are
likely to be catastrophic, acute, and transient, but rarely yielding
chronic disease. Comparatively, homeostatic systems with
adjustable set points provide a greater degree of adaptability,
but are vulnerable to dysregulation and disease when the set
points of the system are changed inappropriately, as often hap-
pens during chronic inflammation. Thus, the flexibility and
adjustment of physiological and developmental characteristics,
while providing a benefit of more efficient adaptation, are also
responsible for the diseases of homeostasis. Treatment and pre-
vention of diseases of homeostasis therefore will require a better
understanding of the mechanisms responsible for the switch be-
tween developmental trajectories and homeostatic set points.Summary
Here, we present a framework that highlights the fundamental
connections between homeostasis and inflammation. This
framework is based on concepts previously developed in control
theory and system dynamics theory. The key points of the frame-
work are summarized below:
d Homeostasis maintains essential parameters of the sys-
tem within acceptable range. These parameters are regu-
lated variables or stocks of the system. The processes
that change or maintain these parameters are known as
flows. The activity of the flow is a parameter known as
controlled variable.
d Homeostatic systems have two components: Controllers
and Plants. Controllers monitor the stocks while Plants op-
erate the flows.
d If the value of regulated variable (X) differs from the set
point value (X’), Controllers produce signals (S) that act
on Plants to change the relevant flows.
d Controller output is proportional to the error value jX-X’j.
The coefficient of proportionality is a characteristic known
as Controller’s gain.
d Controllers can have a combination of different gains: pro-
portional gain corresponds to the present error value, inte-
gral gain corresponds to the accumulated past error
values, and differential gain corresponds to the anticipated
future error value. The Controllers that have all three gains
are known as PID (proportional, integral, differential)
Controllers.
d The gain of Controller can be tuned to change the setting
of the system. In PID Controllers different gains can be
tuned independently of each other to optimize system’s
performance.
d Homeostatic systems can have a single fixed set point, or
multiple adjustable set points. The former are inflexible but
robust to dysregulation. The latter are more adaptable but
vulnerable to dysregulation. Chronic homeostatic diseases
can result when the system becomes locked in an alterna-
tive stable state.
d Plants have their own stocks. A special case of Plant stock
is Storage stock. Storage stocks buffer the System stock
from external fluctuations. System stock, Plant stock and
Storage stock are connected by flows. Stocks connected
by flows form nested homeostatic units, where each stock
is regulated coordinately with other connected stocks.
d Homeostatic signals fall into four classes defined by the
four types of homeostatic variables they report on: System
stock, Plant stock, Storage stock and the flows. Each ofthese variables and the signals that report on them, pro-
vide different information about homeostatic system:
B System stock—information about the present value of
regulated variable and its deviation from set point. Re-
ported by classical endocrine hormones and efferents
of the autonomic nervous system.
B Plant stock—information about the homeostatic ca-
pacity of individual Plants tomaintain the System stock.
Reported by non-endocrine tissue derived hormones.
B Storage stock—information about the amount of re-
sources available to the system. Some storage stocks
may reflect the accumulated past deviations of System
stock from set point. Reported by hormones produced
by tissues that serve as depots for regulated variables.
B Flows—information about the anticipated change in
the System stock. Reported by hormones produced
by tissues that operate flows with large impact on Sys-
tem stock.
d Homeostaticsignalsaffect two typesofvariables:Plantflows
and Controller’s gains. In addition, the sensitivity of Control-
lers andPlants to homeostatic signals can alsobe regulated.
d Signals that report on Storage stock tune the integral gain
of Controllers, whereas signals that report on flows tune
the differential gain of Controllers.
d Inflammatory signals target the same control points as the
homeostatic signals: these are Plant flows and Controller’s
gains. In addition to directly affecting these parameters, in-
flammatory signals canmodulate the sensitivity of Control-
lers and Plants to homeostatic signals.
d Inflammatory response aims to restore homeostasis, but to
achive this goal it has to suppresses incompatible lower
priority homeostatic processes. Therefore, inflammatory
signals are antagonistic to the incompatible homeostatic
signals.
d Inflammatory signals are dominant over homeostatic sig-
nals because they have higher priority. Physiological prior-
ities determine the hierarchy of signals.
d The parallels between homeostatic and inflammatory sig-
nals suggest the evolutionary origin of inflammation as a
control system that complements the homeostatic control
when the latter is insufficient.
d Inflammation can change homeostatic settings of a system
by changing Controller’s gains and by overriding homeo-
static signals. Inflammation commonly accompanies ho-
meostatic diseases associated with set point changes.ACKNOWLEDGMENTS
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